Tue, February 24, 2009
Mon, February 23, 2009
[ Mon, Feb 23rd 2009 ] - Market Wire
Amedisys to Host Investor Day
Sun, February 22, 2009
Fri, February 20, 2009
Thu, February 19, 2009
[ Thu, Feb 19th 2009 ] - Market Wire
Enzon Reports 2008 Results
Wed, February 18, 2009
Tue, February 17, 2009
Mon, February 16, 2009
Fri, February 13, 2009
Thu, February 12, 2009
Wed, February 11, 2009
Tue, February 10, 2009
Mon, February 9, 2009
Sun, February 8, 2009
Fri, February 6, 2009
Thu, February 5, 2009

Biovail Announces Fourth-Quarter 2008 Earnings Release, Conference-Call Details


//health-fitness.news-articles.net/content/2009/ .. 08-earnings-release-conference-call-details.html
Published in Health and Fitness on Thursday, February 12th 2009 at 12:29 GMT, Last Modified on 2009-02-12 12:29:39 by Market Wire   Print publication without navigation


TORONTO--([ BUSINESS WIRE ])--Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced that it will host a conference call and Webcast on Thursday, February 26, 2009, at 8:30 a.m. EST, for Company executives to discuss fourth-quarter 2008 financial and operational results.

Following the discussion, Biovail executives will address inquiries from investment analysts.

A live Webcast of this call will be available through the Investor Relations section of Biovail's Web site at [ www.biovail.com ]. To access the call live, please dial 416-641-6124 (Toronto and International callers) and 1-866-299-8690 (U.S. and Canada). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7 p.m. EST on Thursday, March 5, 2009, by dialing 416-695-5800 (Toronto and International callers) and 1-800-408-3053 (U.S. and Canada), using access code, 3282380#.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets. For more information about Biovail, visit the Company's Web site at [ www.biovail.com ].

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to [ ir@biovail.com ].


Publication Contributing Sources